0001628280-24-000698.txt : 20240105
0001628280-24-000698.hdr.sgml : 20240105
20240105173336
ACCESSION NUMBER: 0001628280-24-000698
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240103
FILED AS OF DATE: 20240105
DATE AS OF CHANGE: 20240105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wise John Drayton
CENTRAL INDEX KEY: 0001930805
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30739
FILM NUMBER: 24517651
MAIL ADDRESS:
STREET 1: 700 US HIGHWAY 202/206
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INSMED Inc
CENTRAL INDEX KEY: 0001104506
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 541972729
STATE OF INCORPORATION: VA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 US HIGHWAY 202/206
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
BUSINESS PHONE: 908-977-9900
MAIL ADDRESS:
STREET 1: 700 US HIGHWAY 202/206
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: INSMED INC
DATE OF NAME CHANGE: 20000128
4
1
wk-form4_1704494003.xml
FORM 4
X0508
4
2024-01-03
0
0001104506
INSMED Inc
INSM
0001930805
Wise John Drayton
700 US HIGHWAY 202/206
BRIDGEWATER
NJ
08807
0
1
0
0
Chief Commercial Officer
1
Stock Option (right to buy)
2024-01-03
4
M
0
20071
19.11
A
124055
D
Stock Option (right to buy)
2024-01-03
4
S
0
20071
29.19
D
103984
D
Common Stock
2024-01-04
4
A
0
12873
A
116857
D
Common Stock
2024-01-05
4
S
0
1167
29.32
D
115690
D
Stock Option (right to buy)
19.11
2024-01-03
4
M
0
20071
0
D
2024-02-10
Common Stock
20071
0
D
Stock Option (right to buy)
29.13
2024-01-04
4
A
0
63560
0
A
2034-01-04
Common Stock
63560
63560
D
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Includes 1,303 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
This is the weighted average sales price representing 20,071 shares sold at prices ranging from $28.915 to $29.39 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant.
Each Restricted Stock Unit was received as a grant on January 4, 2024, for no consideration.
Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees.
Stock options granted under the Company's 2013 Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant.
Stock options granted under the Company's Amended and Restated 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant.
/s/ John Drayton Wise, by Michael A. Smith as Attorney-in-fact
2024-01-05